Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 26 Show results per page	View Search Criteria \| Help With Results

Last Modified: 3/28/2007 First Published: 2/20/2004


1.		Phase I/II Study of FR901228 (Depsipeptide) Alone or in Combination With Rituximab and Fludarabine in Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				MSGCC-0307 NCI-6015, 6015, NCT00079443

Last Modified: 3/14/2008 First Published: 5/28/2004


2.		Phase I/II Study of FR901228 (Depsipeptide) in Patients With Recurrent High-Grade Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				NABTC-0303 NABTC-03-03, NCT00085540, NCI-05-C-0098


3.		A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				GPI-06-0003 NCT00379639

Last Modified: 6/7/2006 First Published: 7/1/2000


4.		Phase II Study of FR901228 (Depsipeptide) in Patients With Refractory or Progressive Small Cell or Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-00-C-0123 NCI-1053, 1053, NCT00020202

Last Modified: 7/16/2008 First Published: 3/1/2001


5.		Phase II Study of FR901228 (Depsipeptide) in Patients With Cutaneous T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, or Other Mature T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCI-01-C-0049 NCI-1312, NCT00020436, 1312

Last Modified: 7/11/2008 First Published: 8/1/2002


6.		Phase II Pilot Study of FR901228 (Depsipeptide) in Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Intermediate-Grade or Follicular Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				MSKCC-00116 NCI-1715, 1715, NCT00042822

Last Modified: 3/9/2007 First Published: 5/23/2003


7.		Phase II Study of FR901228 (Depsipeptide) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UCCRC-12209B NCI-5965, NCT00062075, 5965

Last Modified: 3/9/2007 First Published: 7/26/2003


8.		Phase II Study of FR901228 (Depsipeptide) in Patients With Relapsed or Refractory Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				AECM-0403765 NCI-5996, NCT00066638, 5996

Last Modified: 6/7/2006 First Published: 1/23/2004


9.		Phase II Study of FR901228 (Depsipeptide) in Patients With Relapsed or Refractory Burkitt's, Mantle Cell or Diffuse Large Cell Non-Hodgkin’s Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MAYO-MC0287 NCI-5961, 5961, NCT00077194

Last Modified: 6/6/2006 First Published: 1/23/2004


10.		Phase II Study of FR901228 (Depsipeptide) in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Over 18				NCI				SWOG-S0336 S0336, NCT00077337

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute